Fecal microbiota transplantation in gastrointestinal diseases: what practicing physicians should know.

Fecal microbiota transplantation in gastrointestinal diseases: what practicing physicians should know. Pol Arch Med Wewn. 2015 Sep 23; Authors: Borody T, Connelly N, Mitchell SW Abstract Clostridium difficile infection (CDI) is one of the most commonly reported nosocomial pathogens in the United States (US) and Europe with recent US CDI-associated mortality approaching 30,000 deaths annually. Antibiotics remain the preferred CDI treatment, however a minority of patients experience numerous relapses and are treated with restoration of the bowel microbiota, termed fecal microbiota transplantation (FMT). FMT involves the introduction of a fecal suspension from a healthy donor into the gut of the infected patient to cure the CDI and replace depleted components of the gut microbiota. FMT is particularly effective and safe in curing CDI using a colonoscope or enema to deliver 1-2 infusions. Given that 6425 CDI were reported in Poland in 2014 practicing physicians should understand the benefits and limitations of FMT in CDI as this novel therapy has rapidly advanced to the level of 'standard-of-care' status in Australia, the US and many parts of Europe. FMT has been administered either as a suspension in saline, a highly refined liquid product which can be frozen, as lyophilised powder in capsules, and as an encapsulated spore preparation. The ultimate products to reach the market will be shaped by the indications approved by regulatory bod...
Source: Polskie Archiwum Medycyny Wewnetrznej - Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research